DC/CIK维持治疗晚期非小细胞肺癌的临床观察  

Clinical observation of dendritic cells / cytokine-induced killer cells as maintenance therapy in patients with advanced non-small cell lung cancer

作　　者：吴标[1] 郭增清[1] 王丽莉[1] 陈淑萍[2] 叶韵斌[2] 黄诚[1] 

机构地区：[1]福建省肿瘤医院内科,福州350014 [2]福建省肿瘤医院肿瘤免疫学研究室福建省肿瘤转化医学重点实验室,350014

出　　处：《临床肿瘤学杂志》2014年第10期917-920,共4页Chinese Clinical Oncology

摘　　要：目的：评价树突状细胞联合自体细胞因子诱导杀伤细胞（ DC/CIK）维持治疗晚期非小细胞肺癌（ NSCLC）的疗效和不良反应。方法根据治疗情况将2010年1月至2014年1月120例含铂方案化疗4～6个周期后疾病稳定的晚期NSCLC患者分为对照组（ n＝65）和研究组（ n＝55），仅研究组化疗后接受DC/CIK维持治疗。对两组进行生存随访并比较中位无进展生存期（ PFS）和总生存期（ OS），同时记录不良反应情况。结果研究组的中位PFS为5．0个月，高于对照组的3．5个月，差异有统计学意义（P＜0．05）；研究组的中位OS为8．5个月，与对照组（8．0个月）的差异无统计学意义（P＞0．05）；两组化疗后获不同疗效亚组中位PFS和OS的差异均无统计学意义（ P＞0．05）。常见不良反应为骨髓抑制、发热、乏力和关节酸痛，两组不良反应发生率的差异无统计学意义（ P＞0．05）。结论 DC/CIK维持治疗可延长化疗后疾病稳定晚期NSCLC患者的进展时间，且不良反应轻，患者可耐受。Objective To evaluate the toxicity and efficacy of dendritic cells/cytokine-induced killer cells （ DC/CIK） as the maintenance therapy for advanced non-small cell lung cancer （ NSCLC） . Methods During January 2010 and January 2014, 120 ad-vanced NSCLC patients in stable condition were enrolled after 4-6 cycles chemotherapy containing platinum. According to the treatment, patients were assigned into control group （ n=65） and study group （ n=55） . Only the study group received DC/CIK maintenance ther-apy. Both groups were followed up and the progression free survival （ PFS） and overall survival （ OS） were compared. Moreover, the adverse reaction was recorded. Results The median PFS and OS were 5. 0 and 8. 5 months in study group and 3. 5 and 8. 0 months in control group, respectively. The median PFS was higher in study group versus control group （ P〈0. 05） . No significant differences were observed on median OS between both groups. In addition, there were similar median PFS and OS between different chemotherapeutic efficacy of sub-group. The common adverse reaction included myelosuppression, fever, fatigue and joint pain. The differences of both groups were not statistically significant （ P〉0. 05） . Conclusion DC/CIK as the maintenance therapy can prolong the progression of advanced NSCLC patients in stable condition with tolerable and low adverse reaction.

关 键 词：树突状细胞 细胞因子诱导杀伤细胞 维持治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]